{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:12:58Z","timestamp":1770739978342,"version":"3.49.0"},"reference-count":26,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1253\/circj.cj-11-1076","type":"journal-article","created":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T05:20:29Z","timestamp":1317792029000},"page":"2534-2536","source":"Crossref","is-referenced-by-count":6,"title":["Cilostazol to Overcome High On-Treatment Platelet Reactivity in Korean Patients Treated With Clopidogrel and Calcium-Channel Blocker"],"prefix":"10.1253","volume":"75","author":[{"given":"Young-Hoon","family":"Jeong","sequence":"first","affiliation":[{"name":"Sinai Center for Thrombosis Research"},{"name":"Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[{"name":"Sinai Center for Thrombosis Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin P.","family":"Bliden","sequence":"additional","affiliation":[{"name":"Sinai Center for Thrombosis Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[{"name":"Sinai Center for Thrombosis Research"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.","DOI":"10.1016\/j.jacc.2010.04.047"},{"key":"2","unstructured":"2. Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary Syndrome (TRA·CER) (StudyP04736AM2). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00527943?term=SCH+530348&rank=3 (accessed September 20, 2011)"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708.","DOI":"10.1056\/NEJMoa1105819"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04034.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Liu Y, Shakur Y, Kambayashi J. Phosphodiesterases as targets for intermittent claudication. Handb Exp Pharmacol 2011; 204: 211-236.","DOI":"10.1007\/978-3-642-17969-3_9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kanlop N, Chattipakorn S, Chattipakorn N. Effects of cilostazol in the heart. J Cardiovasc Med 2011; 12: 88-95.","DOI":"10.2459\/JCM.0b013e3283439746"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-11-0113"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: Results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011; 57: 280-289.","DOI":"10.1016\/j.jacc.2010.08.631"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takagi H, Umemoto T. Benefit, rather than safety, of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized trials. Int J Cardiol 2011 Aug 16 [Epub ahead of print].","DOI":"10.1016\/j.ijcard.2011.07.072"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Can Med Assoc J 2006; 174: 1715-1722.","DOI":"10.1503\/cmaj.060664"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Abell LM, Liu EC. Dissecting the activation of thienopyridines by cytochrome P450's using a pharmacodynamic assay in vitro. J Pharmacol Exp Ther 2011 Aug 9 [Epub ahead of print].","DOI":"10.1124\/jpet.111.184895"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0835-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al; DECLARE-LONG II Study Investigators. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: Results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 2011; 57: 1264-1270.","DOI":"10.1016\/j.jacc.2010.10.035"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.025"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2010.12.010"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kim IS, Jeong YH, Park Y, Yun SE, Kwon TJ, Park JR, et al. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: Results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Br J Clin Pharmacol 2011 (in press).","DOI":"10.1111\/j.1365-2125.2011.04131.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, et al. A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 2010; 8: 817-827.","DOI":"10.1111\/j.1538-7836.2010.03769.x"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.016758"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.90"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Suri A, Forbes WP, Bramer SL. Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet 1999; 37(Suppl 2): 61-68.","DOI":"10.2165\/00003088-199937002-00007"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 2011 Jun 23 [Epub ahead of print].","DOI":"10.1136\/hrt.2011.227272"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.122474"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET\/OFFSET study. Circulation 2009; 120: 2577-2585.","DOI":"10.1161\/CIRCULATIONAHA.109.912550"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000072771.11429.83"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.","DOI":"10.1016\/j.jacc.2010.12.047"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.290"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/circj\/75\/11\/75_CJ-11-1076\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T04:02:51Z","timestamp":1616644971000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/circj\/75\/11\/75_CJ-11-1076\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-11-1076","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}